Soria, A. (Ainara)

Filtering

2015 - 201922020 - 20232

Settings

Author search.filters.isAuthorOfPublication.7d7871c8-9615-4064-96aa-c7c20bd468c8

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    SEOM clinical guideline for the management of malignant melanoma (2017)
    (Springer, 2018) Gonzalez-Larriba, J.L. (José Luis); Soria, A. (Ainara); Espinosa, E. (E.); Martin-Algarra, S. (Salvador); Cao, M.G. (M. G.); Arance, A. (Ana); Marquez-Rodas, I. (Iván); Cruz, L. (L.) de la; Castellon, V.E. (V. E.); Berrocal, A. (Alfonso)
    All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
  • Thumbnail Image
    Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
    (2020) Longo, F. (Federico); Tersago, D. (Dominique); Ponce, S. (Santiago); Jove, M. (Maria); Calles, A. (Antonio); Sempere-Ortega, C. (Cayetano); Martín-Echarri, M. (Miguel); Soria, A. (Ainara); López-Tarruella, S. (Sara); Martin-Algarra, S. (Salvador); Rodriguez-Ruiz, M.E. (María Esperanza); Aznar, M.A. (María Ángela); Jiménez-Aguilar, E. (Elisabeth); Castañon, E. (Eduardo); Marquez-Rodas, I. (Iván); Alvarez, R. (Rosa); Calvo, A. (Aitana); Quintero, M. (Marisol); Ponz-Sarvise, M. (Mariano); Gómez-Rueda, A. (Ana); Lopez-Casas, P. (Pedro); Melero, I. (Ignacio); Rubio, B. (Belén); de Miguel, E. (Enrique); Gajate, P. (Pablo); Perez-García, J. (José); Ramos-Medina, R. (Rocío)
    Intratumoral therapies, especially Toll-like receptor agonists, can trigger both the innate and adaptive immune systems. BO-112 is a nanoplexed form of polyinosinic:polycytidylic acid (poly I:C) that induces local and systemic immunotherapeutic effects in mouse models. In a multicenter phase 1 clinical trial, repeated intratumoral administrations of BO-112 induced an increase in tumor cell necrosis and apoptosis, as well as augmented immune reactivity according to gene expression profiling. The first three cohorts receiving BO-112 as a monotherapy resulted in a recommended dose of 1 mg that could be safely repeated. Two grade 3 to 4 adverse reactions in the form of reversible thrombocytopenia were reported. In a fourth cohort of 28 patients with tumors that had primary resistance to anti–programmed cell death protein–1 (PD-1), the combination of intratumoral BO-112 with nivolumab or pembrolizumab was also well tolerated, and 3 patients (2 with melanoma and 1 with renal cell carcinoma) achieved partial responses, with 10 more patients having stable disease at 8 to 12 weeks. Thus, local BO-112 combined with a systemic anti–PD-1 agent might be a strategy to revert anti–PD-1 resistance
  • Thumbnail Image
    SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
    (2023) López-Criado, P. (Pilar); Fernández-Morales, L.A. (Luis Antonio); Boada, A. (Aram); Feito-Rodríguez, M. (Marta); Carrera, C. (Cristina); Yelamos, O. (Oriol); Gonzalez-Cao, M. (María); Luna-Fra, P. (Pablo); Soria, A. (Ainara); Valles, L. (Lara); Antoñanzas-Basa, M. (Mónica); Martin-Algarra, S. (Salvador); Sequero, S. (Silvia); Martin-Liberal, J. (Juan); Villalobos, L. (Laura); Aguayo-Zamora, C. (Cristina); Cruz, R. (Raquel); Marquez-Rodas, I. (Iván); Maldonado-Seral, C. (Cayetana); Manzano, J.L. (José Luis); García-Castaño, A. (Almudena); Puig, S. (Susana); González-Barrallo, I. (Inés); López-Castro, R. (Rafael); Cerezuela, P. (Pablo); Muñoz, E. (Eva); Gardeazabal, J. (Jesús); Rubio, B. (Belén); Feltes-Ochoa, R. (Rosa); Puertolas, T. (Teresa); Drozdowskyj, A. (Ana); Rodrigo, A. (Alberto); Rodríguez-Jiménez, P. (Pedro); Provencio, M. (Mariano); Martínez-Vila, C. (Clara); Berrocal, A. (Alfonso); Crespo, G. (Guillermo); Rodríguez-Moreno, J.F. (Juan Francisco); Mujica, K. (Karmele); Ayala-De-Miguel, P. (Pablo)
    Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ( GRAVID ).Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021.Results One hundred-fifty cases were registered. Median age was 68 years (range 6-95), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: February-May 2020, August-November 2020, and December 2020-April 2021. The first wave had the highest number of registered cases and COVID-19 mortality.Conclusion Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection.
  • Thumbnail Image
    Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 Study
    (Public Library of Science, 2015) Aviles-Izquierdo, J.A. (José Antonio); Spanish Multidisciplinary Group of Melanoma; Gonzalez-Cao, M. (María); Palomar, V. (Virginia); Soria, A. (Ainara); Campos, B. (Begoña); Perez-Ruiz, E. (Elisabeth); Martin-Algarra, S. (Salvador); Galvez, E. (Elisa); Arance, A. (Ana); Maldonado-Seral, C. (Cayetana); Ochoa-de-Olza, M. (María); Gil-Arnaiz, I. (Irene); Nagore, E. (Eduardo); Martin-Carnicero, A. (Alfonso); Gomez-Fernandez, C. (Cristina); Cerezuela, P. (Pablo); Godoy, E. (Elena); Marques-Rodas, I. (Iván); Puertolas, T. (Teresa); Belon, J. (Joaquín); Cruz-Merino, L. (Luis) de la; Martin-Gonzalez, M. (Manuel); Majem-Tarruella, M. (Margarita); Maseda, R. (Rocío)
    Similar to that observed in other countries, familial melanoma accounts for 6.6% of melanoma diagnoses in Spain. Although no differences in the multivariate analysis were found, some better prognosis factors, such as Breslow index, seem more frequent in familial melanoma, which reflect a better early detection marker and/or a different biological behavior.